EP3948286B1 - Krebsprognose - Google Patents

Krebsprognose

Info

Publication number
EP3948286B1
EP3948286B1 EP20706738.0A EP20706738A EP3948286B1 EP 3948286 B1 EP3948286 B1 EP 3948286B1 EP 20706738 A EP20706738 A EP 20706738A EP 3948286 B1 EP3948286 B1 EP 3948286B1
Authority
EP
European Patent Office
Prior art keywords
cancer
patient
parameters
mortality
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20706738.0A
Other languages
English (en)
French (fr)
Other versions
EP3948286A1 (de
Inventor
Dominik Ruettinger
Anna BAUER-MEHREN
Tim Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of EP3948286A1 publication Critical patent/EP3948286A1/de
Application granted granted Critical
Publication of EP3948286B1 publication Critical patent/EP3948286B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Definitions

  • the present invention relates to computer-implemented methods of assessing whether a cancer patient is at high risk or low risk of mortality, as well as methods of predicting the treatment response to an anti-cancer therapy in a cancer patient.
  • the methods of the invention find application in the selection of patients for clinical trials, the selection of patients for treatment with anti-cancer therapies, monitoring cancer patients during treatment with an anti-cancer therapy, and evaluating the results of clinical trials for anti-cancer therapies, for example.
  • the present inventors have further shown that the use of 13 of the 26 parameters of the RoPro1 allows the risk of mortality to be predicted with an accuracy close to that achieved with the use of all 26 parameters, and that the use of as few as 4 or the 26 parameters is sufficient to predict risk of mortality of patients with significantly greater accuracy than RMHS.
  • the present inventors have similarly shown that the use of 13 of the 29 parameters of the RoPro2 allows the risk of mortality to be predicted with an accuracy close to that achieved with the use of all 29 parameters and that the use of as few as 4 of the 29 parameters is sufficient to predict risk of mortality of patients with significantly greater accuracy than RMHS.
  • data corresponding to all thirteen parameters (i) to (xiii) below is selected.
  • a first aspect of the present invention provides a computer-implemented method of assessing risk of mortality of a cancer patient, the method comprising; using a model to generate a score indicative of a risk of mortality of the cancer patient by inputting cancer patient information to the model; and assessing the risk of mortality by comparing the generated score to one or more predetermined threshold values, or by comparing the generated score to generated scores for other cancer patients in a same group, wherein the patient information comprises data corresponding to each of the following parameters:
  • the present inventors have further shown that use of the 26 parameters or 29 parameters, or subsets thereof, are suitable for predicting the treatment response of a cancer patient to an anti-cancer therapy.
  • a method of predicting the treatment response of a cancer patient to an anti-cancer therapy comprising inputting cancer patient information to a model to generate a score indicative of the treatment response of the cancer patient.
  • the patient information may comprise data corresponding to each of the following parameters:
  • the method may further comprise selecting a patient predicted to benefit from treatment with the anti-cancer therapy, for treatment for treatment with the anti-cancer therapy, or treating a patient predicted to benefit from treatment with the anti-cancer therapy with the anti-cancer therapy.
  • Also disclosed but not claimed is a method of treating a cancer patient with an anti-cancer therapy, the method comprising:
  • an anti-cancer therapy for use in a method of treating cancer in a patient, the method comprising predicting the treatment response to an anti-cancer therapy in a cancer patient, the method comprising inputting cancer patient information to a model to generate a score indicative of the treatment response of the cancer patient.
  • the patient information may comprise data corresponding to each of the following parameters:
  • the patient information may comprise, or consist of, data corresponding to more than four parameters selected from parameters (i) to (xiii) but fewer than all of the parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to five, six, seven, eight, nine, ten, eleven, or twelve parameters selected from parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to all thirteen parameters selected from parameters (i) to (xiii).
  • the patient information comprises, or consist of, data corresponding to at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, or all thirteen parameters selected from parameters (i) to (xiii). More preferably, the patient information comprises, or consist of, data corresponding to at least five, at least six, at least seven, at least eight, or at least nine parameters selected from parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to at least five parameters selected from the parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to at least six parameters selected from the parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to at least seven parameters selected from parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to at least eight parameters selected from parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to at least nine parameters selected from parameters (i) to (xiii).
  • the patient information may comprise, or consist of, data corresponding to all of parameters (i) to (v).
  • the inventors have found that selecting these parameters can improve the accuracy of the assessment of mortality risk.
  • the treatment response to an anti-cancer therapy in a cancer patient may be a complete response, progression-free survival, a partial response, or cancer progression.
  • a complete response may refer to the absence of detectable disease (cancer) in the patient.
  • Progression-free-survival may refer to survival of the patient for a period of time during which there is no worsening of the disease (cancer).
  • a partial response may refer to a decrease in the size of the tumour(s) or reduction in the spread of the cancer in the patient's body.
  • a complete response (also referred to as complete remission) may refer to the absence of detectable disease in the patient.
  • Cancer progression may refer to a worsening of the disease (cancer), such as an increase in tumour size and/or an increase in the number of tumours in the patient's body.
  • Methods of detecting a complete response, particle response, progression-free survival and cancer progression in a cancer patient in response to an anti-cancer therapy are well known in the art.
  • the patient information may further comprise data corresponding to one or more parameters selected from:
  • the patient information may further comprises data corresponding to one or more parameters selected from:
  • the patient information may comprise data corresponding to more than one parameter selected from parameters (xiv) to (xxvi) and/or (xxvii) to (xxix).
  • the patient information may additionally or alternatively comprise data corresponding to at least two, at least three, art least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, or all thirteen of the parameters selected from parameters (xiv) to (xxvi) and/or at least one, at least two, or all three parameters selected from parameters (xxvii) to (xxix).
  • parameters other than (i) to (xxvi) or (i) to (xxix) may also be included in the patient information and training data.
  • the patient information may comprise data corresponding to at least seven parameters selected from parameters (i) to (xxix), wherein at least one parameter is selected from parameters (xxvii) to (xxix).
  • the cancer patient information may comprise data corresponding to at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, at least twenty-one, at least twenty-two, at least twenty-three, at least twenty-four, at least twenty-five, at least twenty-six, at least twenty-seven, or at least twenty-eight parameters selected from parameters (i) to (xxix), wherein at least one parameter is selected from parameters (xxvii) to (xxix).
  • the selected parameter(s) from parameters (xxvii) to (xxix), preferably is or includes parameter (xxvii) (lymphocyte level in blood).
  • the patient information may comprise data corresponding to parameter (xxvii) and five or more parameters selected from parameters (i), (ii), (iii), (v), (vi), (vii), (viii), (ix), (xi), (xviii), and (xxiii).
  • a useful score may be obtained even if not all of the parameters are available for a patient. So, the number of parameters selected for the patient information, may be fewer than the number of parameters included in the training data. For example, if a model is formed using training data including all of the parameters (i) to (xxvi) or (i) to (xxix), the patient information can include less than all of these parameters and a score with similar accuracy can still be produced. For example, 13, 14, 15 or 16 parameters from the list (i) to (xxvi) or (i) to (xxix) may be input to a model including all of the parameters (i) to (xxvi) or (i) to (xxix). This increases the ease of use of the method as the method can still assess patients with missing patient information.
  • Training data may be obtained from a database, which may be derived from electronic health record data.
  • the database and/or the training data may include structured and/or unstructured data.
  • Subjects in the training data may be cancer patients.
  • Subjects may be included or excluded from the training data based on cancer-type. For example, in order to tailor the method to a patient with a first cancer type, the training data may exclude subjects that do not have the first cancer type.
  • Data may be screened so that insignificant parameters are excluded from the model.
  • the inventors have found the parameters (i) to (xxvi) and (i) to (xxix) to be significant in assessment of mortality risk and the prediction of the treatment response to an anti-cancer therapy, with a model employing parameters (i) to (xxix) outperforming a model employing parameters (i) to (xxvi).
  • Screening may comprise analysing each parameter using Bonferroni-correction and excluding parameters with a p-value larger than a threshold value. For example, parameters with a p-value of 0.05 divided by the number of parameters considered or larger may be excluded from the training data. Parameters may be included in the model in the order of their significance (predictive value) during screening.
  • a model may be formed by including the selected parameters from parameters (i) to (xxvi) in this order.
  • the patient information may thus comprise or consist of data corresponding to the parameters with ranks 1 to 4, 1 to 5, 1 to 6, 1 to 7, 1 to 8, 1 to 9, 1 to 10, 1 to 11, 1 to 12, 1 to 13, 1 to 14, 1 to 15, 1 to 16, 1 to 17, 1 to 18, 1 to 19, 1 to 20, 1 to 21, 1 to 22, 1 to 23, 1 to 24, 1 to 25, or 1 to 26 in RoPro1 as set out in Table 15, whereby the parameters with ranks 1 to 4 in RoPro1 correspond to the level of albumin in serum or plasma, ECOG performance status, ratio of lymphocytes to leukocytes in blood, and smoking status.
  • a model may be formed by including the selected parameters from parameters (i) to (xxix) in the rank order shown in Table 15.
  • Parameters (i) to (xxix) above, as well as the substitute parameters referred to herein, may be measured at any suitable time point.
  • the parameters may be measured at a first time point and a second time point, whereby the first time point may be before administration of the first dose of the anti-cancer therapy to the patient and the second time point may be after administration of the anti-cancer therapy to the patient, whereby an improvement in the predicted treatment response at the second time point compared with the first time point indicates that patient is responding to the anti-cancer therapy, and a deterioration in the predicted treatment response at the second time point compared with the first time point indicates that patient is not responding or has become resistant to the anti-cancer therapy.
  • the training data may include patient information comprising parameter data for a plurality of subjects.
  • the plurality of subjects may include at least 10000 subjects. Using a large number of subjects increases the accuracy of the model.
  • the plurality of subjects may include at least 15000, 20000, 30000, 40000, 50000, 60000, 70000, 80000, or 90000 subjects.
  • Methods of predicting the treatment response of a cancer patient to an anti-cancer therapy may comprise comparing a score generated by the model to one or more predetermined threshold values, or comparing the generated score to generated scores for other cancer patients in a same group, to obtain the prediction of the treatment response.
  • the method may, for example, comprise determining whether the generated score is above or below a predetermined threshold value or in a range of values between two different predetermined threshold values.
  • the risk of mortality may be assessed as a high risk or a low risk.
  • a patient may be assessed as at high risk of mortality if their score is above 0, or above 1, or above 1.05.
  • a patient may be assessed as at low risk of mortality if their score is below 0 or below - 1 or below -1.19.
  • the risk of mortality may be assessed as very high risk if the RoPro score is above 1.13.
  • the risk of mortality may be assessed as lower if the RoPro score is below 1.13.
  • the risk of mortality may be assessed as very high if the RoPro score is above 0.81.
  • an advanced melanoma-specific RoPro score the risk of mortality may be assessed as very high if the RoPro score is above 1.06.
  • the risk of mortality may be assessed as very high if the RoPro score is above 0.94.
  • the risk of mortality may be assessed as very high if the RoPro score is above 1.22.
  • the risk of mortality may be assessed as very high if the RoPro score is above 1.02.
  • the risk of mortality may be assessed as very high if the RoPro score is above 1.04.
  • the risk of mortality may be assessed as very high if the RoPro score is above 0.89.
  • the risk of mortality may be assessed as very high if the RoPro score is above 0.75.
  • the risk of mortality may be assessed as very high if the RoPro score is above 1.60.
  • the risk of mortality may be assessed as very high if the RoPro score is above 0.87.
  • a patient may be assessed as at high risk of mortality if their score is within the range of the highest 50% or the highest 10% or the highest 5% of scores for the plurality of subjects.
  • a patient may be assessed as at low risk of mortality if their score is within the range of the lowest 50% or the lowest 10% or the lowest 5% of scores for the plurality of subjects.
  • the term ratio may refer to a scaled ratio.
  • the ratio of lymphocytes to leukocytes in blood may be the number of lymphocytes per 100 leukocytes.
  • the ratio of eosinophils to leukocytes in blood may be the number of eosinophils per 100 leukocytes.
  • the present invention relates to a method of selecting cancer patients for inclusion in a clinical trial, e.g. for an anti-cancer therapy, the method comprising identifying a first and a second cancer patient with the same risk of mortality using a method as described herein, and including said patients in the clinical trial.
  • the first cancer patient may receive the anti-cancer therapy and the second cancer patient may not receive the anti-cancer therapy.
  • the second cancer patient acts as a control for the first cancer patient, thereby allowing e.g. the safety or efficacy of the anti-cancer therapy to be evaluated.
  • both the first and the second patient has a low risk of mortality.
  • Patients may be judged to have the same risk of mortality if they are both assessed as having a low risk or are both assessed as having a high risk. Alternatively, patients may be judged as having the same risk if their scores are within the same quantile as each other. For example, a set of patients may be grouped into 10% or 5% quantiles based on their scores. Two patients within the top 5% of scores in the set may be judged to have the same risk. Two patients in the second (5-10%) quantile may be judged to have the same risk.
  • Disclosed but not claimed is a method of treating a cancer patient with an anti-cancer therapy, the method comprising assessing whether the cancer patient is at high risk or low risk of mortality using a method as described herein, and administering a pharmaceutically effective amount of the anti-cancer therapy to a patient assessed to be at low risk of mortality.
  • an anti-cancer therapy for use in a method of treating a cancer patient with an anti-cancer therapy, the method comprising assessing whether the cancer patient is at high risk or low risk of mortality using a method as described herein, and administering a pharmaceutically effective amount of the anti-cancer therapy to a patient assessed to be at low risk of mortality.
  • the cancer type-specific parameters referred to above are well known in the art, as are methods for measuring these parameters. Exemplary methods are set out in Table 15. Measuring these parameters is therefore well within the capabilities of the skilled person.
  • the cancer type-specific parameter is a biomarker (e.g. presence or absence of ALK rearrangement, presence or absence of EGFR mutation etc.)
  • information on the presence or absence of the biomarker is included in the patient's electronic health record (EHR).
  • EHR electronic health record
  • Methods for determining the presence or absence of biomarkers include: sequencing, such as next generation sequencing, fluorescent in situ hybridization (FISH), and immunohistochemistry (IHC).
  • the dataset from the Flatiron Health database on the basis of which the 26 parameters of the RoPro1 described above were identified consisted of 99,249 patients with one of the following cancer types: advanced melanoma, advanced non-small-cell lung cancer (NSCLC), bladder cancer, chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma (HCC), metastatic breast cancer, metastatic colorectal cancer (CRC), metastatic renal cell carcinoma (RCC), multiple myeloma, ovarian cancer, or small-cell lung carcinoma (SCLC).
  • NSCLC advanced non-small-cell lung cancer
  • CLL chronic lymphocytic leukaemia
  • DLBCL diffuse large B-cell lymphoma
  • HCC hepatocellular carcinoma
  • metastatic breast cancer metastatic colorectal cancer
  • RRCC metastatic renal cell carcinoma
  • SCLC small-cell lung carcinoma
  • a cancer as referred to herein, may be a cancer selected from the group consisting of: melanoma (such as advanced melanoma)), NSCLC (such as advanced NSCLC), bladder cancer, CLL, DLBCL, HCC, metastatic breast cancer, metastatic CRC, metastatic RCC, multiple myeloma, ovarian cancer, and SCLC.
  • melanoma such as advanced melanoma
  • NSCLC such as advanced NSCLC
  • bladder cancer CLL, DLBCL, HCC, metastatic breast cancer, metastatic CRC, metastatic RCC, multiple myeloma, ovarian cancer, and SCLC.
  • the dataset from the Flatiron Health database on the basis of which the 29 parameters of the RoPro 2 described above were identified consisted of 111,538 patients with one of the following cancer types: advanced melanoma, advanced NSCLC, bladder cancer, CLL, DLBCL, HCC, metastatic breast cancer, metastatic CRC, metastatic RCC, multiple myeloma, ovarian cancer, SCLC, follicular lymphoma, pancreatic cancer or head & neck cancer. Furthermore, the present inventors have shown that patient information comprising data corresponding to parameters set forth in (i) to (xxix) above could be used to predict the risk of mortality in these cancer types.
  • a cancer may be a cancer selected from the group consisting of: melanoma (such as advanced melanoma)), NSCLC (such as advanced NSCLC), bladder cancer, CLL, DLBCL, HCC, metastatic breast cancer, metastatic CRC, metastatic RCC, multiple myeloma, ovarian cancer, SCLC, follicular lymphoma, pancreatic cancer, and head & neck cancer.
  • melanoma such as advanced melanoma
  • NSCLC such as advanced NSCLC
  • bladder cancer CLL, DLBCL, HCC, metastatic breast cancer, metastatic CRC, metastatic RCC, multiple myeloma, ovarian cancer, SCLC, follicular lymphoma, pancreatic cancer, and head & neck cancer.
  • the RoPro1 is a weighted sum over the 26 parameters, (i) to (xxvi), whereas the RoPro 2 is a weighted sum over the 29 parameters, (i) to (xxix), of the difference between the patient's data and the respective reference parameter means.
  • a higher RoPro indicates higher death hazard and a higher mortality risk and a lower RoPro indicates a lower death hazard and a lower mortality risk.
  • the HER2 variable differs from the general RoPro variables, since it directly influences treatment decision.
  • the vast majority of HER2+ patients receive targeted therapy (trastuzumab, pertuzumab, etc.).
  • the respective RoPro term would be miss-specified.
  • a RoPro1 score specific to advance melanoma is given by the formula: -0.03255 (Albumin-39.83) + 0.28838 (ECOG-0.7) + 0.00046 (LDH-286.82) -0.00931 (Lymphocytes/100 Leukocytes-21.7) -0.03681 (Hemoglobin-13.26) + 0.00119 (ALP-90.46) + 0.13144 (NLR-0.61) -0.02788 (Chloride-102.07) + 0.00564 (Heart rate-80.06) + 0.00412 (AST-24.45) + 0.00595 (Age-65.15) + 0.0086 (Urea nitrogen-17.68) -0.04493 (Oxygen-96.89) + 0.12968 (TNM stage-3.03) -0.017 (Protein-69.04) -0.00271 (Systolic RR-131.2) - 0.04086 (Eosinophils/100 Leukocytes-2.53) + 0.00564 (B
  • a RoPro1 score specific to CLL is is given by the formula: -0.03867 (Albumin-41.27) + 0.41112 (ECOG-0.61) + 0.00035 (LDH-257.53) -0.00048 (Lymphocytes/100 Leukocytes-67.49) + 0.00858 (Hemoglobin-11.9) + 0.00322 (ALP-86.29) + 0.003 (NLR-0.16) -0.0278 (Chloride-103.45) + 0.00728 (Heart rate-77.61) + 0.00348 (AST-24.35) + 0.05572 (Age-69.71) + 0.00942 (Urea nitrogen-20.19) -0.07428 (Oxygen-96.72) + 0.01033 (TNM stage-1.38) -0.00604 (Protein-65.51) -0.00352 (Systolic RR-129.82) + 0.01924 (Eosinophils/100 Leukocytes-1.18) + 0.0243 (Bilirubin
  • a RoPro1 score specific to DLBCL is given by the formula: -0.01324 (Albumin-38.76) + 0.41084 (ECOG-0.78) + 0.00051 (LDH-330) -0.00259 (Lymphocytes/100 Leukocytes-21.57) -0.02629 (Hemoglobin-12.33) + 0.00246 (ALP-94.94) -0.14718 (NLR-0.67) -0.01611 (Chloride-101.62) + 0.00186 (Heart rate-83.71) + 0.00324 (AST-27.74) + 0.03897 (Age-65.41) + 0.0115 (Urea nitrogen-18.02) -0.08422 (Oxygen-97.03) + 0.11178 (TNM stage-2.8) -0.01996 (Protein-67.65) + 0.00247 (Systolic RR-129.35) + 0.03503 (Eosinophils/100 Leukocytes-2.42) -0.0067 (Bilirubin-
  • a score specific to multiple myeloma is is given by the formula: -0.03132 (Albumin-37.7) + 0.40645 (ECOG-0.83) + 0.00093 (LDH-203.06) -0.00781 (Lymphocytes/100 Leukocytes-29.79) -0.04835 (Hemoglobin-10.98) + 0.00219 (ALP-82.55) -0.07473 (NLR-0.3) -0.01956 (Chloride-102.06) + 0.00436 (Heart rate-80.65) + 0.00191 (AST-24.06) + 0.03613 (Age-68.6) + 0.01272 (Urea nitrogen-22.03) -0.01123 (Oxygen-97.07) + 0.23461 (TNM stage-1.97) -0.00372 (Protein-82.13) -0.00398 (Systolic RR-134.69) -0.04269 (Eosinophils/100 Leukocytes-2.42) + 0.30565 (Bil
  • a RoPro2 score specific to Advanced NSCLC is given by the formula: 0.00653(AGE-67.981)+0.16544(Gender-0.537)+0.29991(Smoking-0.877)+0.12237(No. of metastatic sites-0.174)+0.19453(ECOG-0.922)+0.02572(NLR-0.766)-0.00725(BMI-26.899)-0.03658(oxygen-95.996)-0.00259(SBP-126.983)+0.00518(heart rate-85.716)-0.04524(Hgb-12.327)+0.00529(Leukocytes-9.807)+0.01222(urea nitrogen-17.129)+0.14336(calcium-9.323)-0.00051(platelets-298.177)-0.01381(lymphocytes/100 leukocytes in blood-16.727)+0.00251(AST-22.414)+0.00144(ALP-102.824)-0.01326(protein-68.696)-0.00416(ALT-
  • a RoPro2 score specific to Advanced Melanoma is given by the formula: 0.0062(AGE-65.539)+0.1059(Gender-0.68)-0.13496(Smoking-0.352)-0.01106(No. of metastatic sites-0.368)+0.2725(ECOG-0.758)+0.10207(NLR-0.594)-0.00161(BMI-28.896)-0.03303(oxygen-97.009)-0.0029(SBP-130.345)+0.00699(heart rate-79.392)-0.02029(Hgb-13.099)-0.00206(Leukocytes-8.308)+0.01633(urea nitrogen-18.031)+0.08373(calcium-9.297)-0.00025(platelets-258.758)-0.01065(lymphocytes/100 leukocytes in blood-21.258)+7e-04(AST-24.439)+0.00058(ALP-94.702)-0.01989(protein-68.102)+0.00155(ALT-25.62)-
  • a RoPro2 score specific to DLBCL (Diffuse large B-cell carcinoma) is given by the formula: 0.038(AGE-66.079)+0.22192(Gender-0.547)-0.22649(Smoking-0.351)+0.11979(No.
  • a RoPro2 score specific to metastatic RCC (renal cell carcinoma) is given by the formula: 0.00638(age-66.118)-0.01476(Gender-0.699)+0.00179(Smoking-0.572)+0.06387(No.
  • a RoPro2 score specific to ovarian cancer is given by the formula: 0.00998(age-65.176)+1.02303(Smoking-0.35)+0.11866(No. of metastatic sites-0.082)+0.25502(ECOG-0.778)+0.21763(NLR-0.555)-0.00348(BMI-28.264)-0.05212(oxygen-96.969)-0.00274(SBP-128.397)+0.00062(heart rate-84.888)-0.02728(Hgb-11.746)+0.01832(Leukocytes-7.828)+0.02424(urea nitrogen-15.932)+0.00599(calcium-9.323)-0.00101(platelets-332.437)+0.01093(lymphocytes/100 leukocytes in blood-21.544)+0.00837(AST-23.971)+0.00353(ALP-91.691)-0.01219(protein-68.922)-0.01376(ALT-21.587)-0.03487(albumin
  • a RoPro2 score specific to SCLC is given by the formula: 0.00891 (age-67.252)+0.22435(Gender-0.481)+0.10511(Smoking-0.985)+0.01216(No.
  • a RoPro2 score specific to head and neck cancer is given by the formula: 0.00518(age-64.674)+0.12697(Gender-0.772)-0.02112(Smoking-0.805)+0.09328(No. of metastatic sites-0.111)+0.16008(ECOG-0.894)-0.04024(NLR-0.775)-0.00764(BMI-24.671)-0.03521(oxygen-96.753)-0.00198(SBP-125.17)+0.00672(heart rate-81.443)-0.05918(Hgb-12.345)+0.01424(Leukocytes-8.344)+0.00502(urea nitrogen-17.085)+0.17451 (calcium-9.441)-8e-05(platelets-276.764)-0.01363(lymphocytes/100 leukocytes in blood-16.982)+0.00467(AST-23.164)+0.00271 (ALP-87.966)-0.00349(protein-69.592)-0.00565(ALT-20
  • a RoPro2 score specific to follicular is given by the formula: 0.0468(age-66.416)+0.70266(Gender-0.516)+1.06061 (No. of metastatic sites-0.012)+0.06024(ECOG-0.556)+0.26978(NLR-0.493)-0.02437(BMI-29.51)-0.17142(oxygen-96.821)+0.00584(SBP-129.754)+0.01086(heart rate-78.578)-0.05796(Hgb-12.858)-0.01222(Leukocytes-7.63)+0.02537(urea nitrogen-17.532)+0.01785(calcium-9.334)-0.00083(platelets-227.01)-0.00522(lymphocytes/100 leukocytes in blood-24.463)+0.01112(AST-22.11)+0.00406(ALP-83.673)+0.01715(protein-67.455)-0.03429(ALT-20.377)-0.07823(albumin-39.938)-
  • a RoPro2 score specific to pancreatic cancer is given by the formula: 0.00638(age-67.378)+0.05687(Gender-0.541)-0.62763(Smoking-0.35)+0.00541(No. of metastatic sites-0.093)+0.22063(ECOG-0.894)+0.03629(NLR-0.667)-0.00469(BMI-26.238)-0.02826(oxygen-97.09)-0.00141(SBP-126.099)+0.00776(heart rate-82.714)-0.0175(Hgb-11.903)+0.00485(Leukocytes-8.717)+0.01408(urea nitrogen-15.205)+0.10756(calcium-9.203)-0.00054(platelets-257.947)-0.00733(lymphocytes/100 leukocytes in blood-19.318)+0.00386(AST-37.701)+0.00114(ALP-185.199)-0.00548(protein-66.673)-0.00654(ALT-37.784)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Evolutionary Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Probability & Statistics with Applications (AREA)
  • Physiology (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (14)

  1. Computerimplementiertes Verfahren zum Bewerten des Mortalitätsrisikos eines Krebspatienten, wobei das Verfahren Folgendes umfasst:
    Verwenden eines Modells zum Erzeugen eines Scores, der ein Mortalitätsrisiko des Krebspatienten angibt, durch Eingeben von Krebspatienteninformationen in das Modell; und
    Bewerten des Mortalitätsrisikos durch Vergleichen des erzeugten Scores mit einem oder mehreren vorbestimmten Schwellenwert(en) oder durch Vergleichen des erzeugten Scores mit erzeugten Scores für andere Krebspatienten in einer selben Gruppe, wobei die Patienteninformationen Daten umfassen, die jedem der folgenden Parameter entsprechen:
    (i) Gehalt von Albumin in Serum oder Plasma;
    (ii) Leistungsstatus gemäß der Eastern Cooperative Oncology Group (ECOG);
    (iii) Verhältnis von Lymphozyten zu Leukozyten im Blut;
    (iv) Raucherstatus;
    (v) Alter;
    (vi) TNM-Klassifikation des Stadiums maligner Tumore;
    (vii) Herzfrequenz;
    (viii) Chlorid- oder Natriumgehalt in Serum oder Plasma;
    (ix) Harnstoffstickstoffgehalt in Serum oder Plasma;
    (x) Geschlecht;
    (xi) Hämoglobin- oder Hämatokritgehalt im Blut;
    (xii) Aspartat-Aminotransferase-Enzymaktivitätsgrad in Serum oder Plasma und
    (xiii) Alanin-Aminotransferase-Enzymaktivitätsgrad in Serum oder Plasma.
  2. Verfahren nach Anspruch 1, wobei die Patienteninformationen ferner Daten umfassen, die einem oder mehreren Parameter(n) entsprechen, der/die aus Folgenden ausgewählt ist/sind:
    (xiv) systolischer oder diastolischer Blutdruck;
    (xv) Lactat-Dehydrogenase-Enzymaktivitätsgrad in Serum oder Plasma;
    (xvi) Körpermasseindex;
    (xvii) Proteingehalt in Serum oder Plasma;
    (xviii) Blutplättchenzahl im Blut;
    (xix) Anzahl an Metastasestellen;
    (xx) Verhältnis von Eosinophilen zu Leukozyten im Blut;
    (xxi) Calciumgehalt in Serum oder Plasma;
    (xxii) Sauerstoffsättigungsgrad im Arterienblut;
    (xxiii) alkalische Phosphatase-Enzymaktivitätsgrad in Serum oder Plasma;
    (xxiv) Neutrophile-zu-Lymphozyten-Verhältnis (NLR) im Blut;
    (xxv) Gesamtbilirubingehalt in Serum oder Plasma und
    (xxvi) Leukozytenzahl im Blut.
  3. Verfahren nach Anspruch 1 oder 2, wobei die Patienteninformationen ferner Daten umfassen, die einem oder mehreren Parameter(n) entsprechen, der/die aus Folgenden ausgewählt ist/sind:
    (xxvii) Lymphozytenzahl im Blut;
    (xxviii) Kohlendioxidgehalt im Blut und
    (xxix) Monozytenzahl im Blut.
  4. Verfahren nach einem der Ansprüche 1-3, wobei das Bewerten des Mortalitätsrisikos das Vorhersagen eines Behandlungsansprechens des Krebspatienten auf eine Antikrebstherapie umfasst.
  5. Verfahren nach Anspruch 4, wobei das Behandlungsansprechen progressionsfreies Überleben, teilweises Ansprechen, vollständiges Ansprechen oder Krebsprogression ist.
  6. Verfahren nach einem vorstehenden Anspruch, wobei das Verfahren ferner das Bilden des Modells mittels Durchführen einer multivariablen Cox-Regressions-Analyse an Trainingsdaten umfasst, wobei die Trainingsdaten die Parameter einschließen, die aus der Liste für eine Vielzahl von Individuen, vorzugsweise mindestens 1.000 Individuen, ausgewählt sind.
  7. Verfahren nach Anspruch 6, wobei das Bilden des Modells Folgendes umfasst:
    Zuordnen einer jeweiligen Wichtung, w, zu jedem der jeweiligen Parameter, die aus der Liste ausgewählt sind, und
    Zuordnen eines jeweiligen Mittelwerts, m, zu jedem der jeweiligen Parameter, die aus der Liste für die Vielzahl von Individuen ausgewählt sind, und
    wobei die Ausgabe des Modells durch eine Summe über die ausgewählten Parameter gemäß der folgenden Formel angegeben wird: Ausgabe = ∑ w Eingabe − m .
  8. Verfahren zum Bewerten des Mortalitätsrisikos eines Krebspatienten nach einem der Ansprüche 1 bis 3, wobei das Verfahren ferner das Bewerten, ob das Mortalitätsrisiko hohes Risiko oder geringes Risiko ist, umfasst.
  9. Verfahren zum Auswählen eines Krebspatienten für die Aufnahme in eine klinische Prüfung, wobei das Verfahren das Bewerten, ob der Krebspatient hohes oder geringes Mortalitätsrisiko aufweist, unter Anwendung eines Verfahrens nach Anspruch 8 und das Auswählen eines Patienten, bei dem bewertet wurde, dass er ein geringes Mortalitätsrisiko aufweist, für die Aufnahme in die klinische Prüfung umfasst.
  10. Verfahren zum Auswählen eines Krebspatienten für die Behandlung mit einer Antikrebstherapie, wobei das Verfahren das Bewerten, ob der Krebspatient hohes oder geringes Mortalitätsrisiko aufweist, unter Anwendung eines Verfahrens nach Anspruch 8 und das Auswählen eines Krebspatienten, bei dem bewertet wurde, dass er ein geringes Mortalitätsrisiko aufweist, für die Behandlung mit der Antikrebstherapie umfasst.
  11. Verfahren zum Überwachen eines Krebspatienten während der Behandlung mit einer Antikrebstherapie, wobei das Verfahren das Bewerten, ob der Krebspatient ein hohes oder geringes Mortalitätsrisiko aufweist, unter Anwendung eines Verfahrens nach Anspruch 8 umfasst, wobei ein Krebspatient, bei dem bewertet wurde, dass er ein geringes Mortalitätsrisiko aufweist, für eine weiterführende Behandlung mit der Antikrebstherapie ausgewählt wird und ein Krebspatient, bei dem bewertet wurde, dass er ein hohes Mortalitätsrisiko aufweist, für einen Abbruch der Behandlung mit der Antikrebstherapie auswählt wird.
  12. Verfahren zum Auswerten der Ergebnisse einer klinischen Prüfung für eine Antikrebstherapie, die an Krebspatienten durchgeführt wurde, wobei das Verfahren das Bewerten, ob die Krebspatienten, die an der klinischen Prüfung teilnehmen, ein hohes oder geringes Mortalitätsrisiko aufweisen, unter Anwendung eines Verfahrens nach Anspruch 8 umfasst.
  13. Verfahren zum Auswählen von Krebspatienten für das Aufnehmen in eine klinische Prüfung, wobei das Verfahren das Identifizieren eines ersten und eines zweiten Krebspatienten mit demselben Mortalitätsrisiko unter Anwendung eines Verfahrens nach Anspruch 8 und das Aufnehmen der Patienten in die klinische Prüfung umfasst.
  14. Verfahren nach einem vorstehenden Anspruch, wobei der Krebs aus der Gruppe ausgewählt ist, die aus Folgendem besteht: Melanom, nichtkleinzelligem Lungenkarzinom (NSCLC), Blasenkrebs, chronischer lymphatischer Leukämie (CLL), diffusem großzelligem B-Zell-Lymphom (DLBCL), Leberzellenkarzinom (HCC), metastatischem Brustkrebs, metastatischem Kolorektalkrebs(CRC), metastatischem Nierenzellenkarzinom (RCC), multiplem Myelom, Eierstockkrebs, kleinzelligem Lungenkarzinom (SCLC), follikulärem Lymphom, Bauchspeicheldrüsenkrebs und Kopf- und Halskrebs.
EP20706738.0A 2019-03-28 2020-02-25 Krebsprognose Active EP3948286B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19166011 2019-03-28
PCT/EP2020/054935 WO2020193045A1 (en) 2019-03-28 2020-02-25 Cancer prognosis

Publications (2)

Publication Number Publication Date
EP3948286A1 EP3948286A1 (de) 2022-02-09
EP3948286B1 true EP3948286B1 (de) 2025-07-23

Family

ID=66001096

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20706738.0A Active EP3948286B1 (de) 2019-03-28 2020-02-25 Krebsprognose

Country Status (5)

Country Link
US (2) US20220165362A1 (de)
EP (1) EP3948286B1 (de)
JP (2) JP7441853B2 (de)
CN (1) CN113614537B (de)
WO (1) WO2020193045A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111613327B (zh) * 2020-05-29 2023-11-14 首都医科大学附属北京朝阳医院 利用基于logistic回归的多发性骨髓瘤诊断模型开发的系统及其应用
WO2022150582A1 (en) * 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
CN113699235B (zh) * 2021-08-20 2023-10-20 山东大学齐鲁医院 免疫原性细胞死亡相关基因在头颈鳞癌生存预后及放疗应答性中的应用
CN114220546A (zh) * 2022-01-04 2022-03-22 陕西中医药大学第二附属医院 一种乙肝肝硬化发生肝癌风险预测模型的建立方法
CN121450803B (zh) * 2026-01-05 2026-06-26 北京市神经外科研究所 评估等离子体治疗肿瘤治疗效果的方法、系统及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2558599A4 (de) * 2010-04-14 2013-11-13 Nuvera Biosciences Inc Verfahren zur bewertung des ansprechens auf eine krebstherapie
US20120084011A1 (en) * 2010-09-30 2012-04-05 Fox Chase Cancer Center Methods for managing cancer patient care
GB201018480D0 (en) * 2010-11-02 2010-12-15 Oxford Biomedica Ltd Factors
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
WO2013029202A1 (zh) * 2011-08-30 2013-03-07 北京沙东生物技术有限公司 谷草转氨酶和乳酸脱氢酶的检测在早期评估抗肿瘤干预措施临床疗效中的应用
RU2640568C2 (ru) 2012-05-03 2018-01-09 Медиал Рисеч Лтд. Способы и системы для оценки риска рака желудочно-кишечного тракта
US9946840B1 (en) * 2013-03-14 2018-04-17 Axon Acuity, Llc Systems and methods for assessing staffing levels and predicting patient outcomes
JP2017021727A (ja) * 2015-07-15 2017-01-26 国立大学法人京都大学 イベント発生時期予測装置、イベント発生時期予測方法、及びイベント発生時期予測プログラム
WO2018081382A1 (en) * 2016-10-26 2018-05-03 Brown University A method to measure myeloid suppressor cells for diagnosis and prognosis of cancer
WO2018134356A1 (en) * 2017-01-20 2018-07-26 Etablissement Français Du Sang Method for predicting the clinical evolution of cancer patients
JP6918353B2 (ja) * 2017-07-24 2021-08-11 公立大学法人横浜市立大学 死亡予測装置及び死亡予測プログラム
WO2019221930A1 (en) * 2018-05-16 2019-11-21 Opko Diagnostics, Llc Methods for detecting prostate cancer pathology associated with adverse outcomes
US20200191792A1 (en) * 2018-10-18 2020-06-18 Medimmune, Llc Methods for determining treatment for cancer patients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSCOE D M ET AL: "Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of pseudomonas exotoxin", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 62, no. 11, 1 November 1994 (1994-11-01), pages 5055 - 5065, XP002968542, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
CN113614537B (zh) 2025-10-17
JP2022526361A (ja) 2022-05-24
WO2020193045A1 (en) 2020-10-01
CN113614537A (zh) 2021-11-05
JP7441853B2 (ja) 2024-03-01
US20250266130A1 (en) 2025-08-21
US20220165362A1 (en) 2022-05-26
EP3948286A1 (de) 2022-02-09
JP2023156317A (ja) 2023-10-24

Similar Documents

Publication Publication Date Title
Liu et al. Multi-omics identification of an immunogenic cell death-related signature for clear cell renal cell carcinoma in the context of 3P medicine and based on a 101-combination machine learning computational framework
Hu et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: a multi-center real-world retrospective study
JP7441853B2 (ja) がんの予後
Vokes et al. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non–small-cell lung cancer
Becker et al. An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort
Rakovitch et al. 21-gene assay and breast cancer mortality in ductal carcinoma in situ
Dong et al. Identification of a Pyroptosis‐Related Gene Signature for Prediction of Overall Survival in Lung Adenocarcinoma
Wind et al. Prognostic significance of pre‐treatment immune‐inflammation biomarkers in anal cancer: A study combining real‐world data and a meta‐analysis
Luo et al. Pyroptosis‐Related Gene Model Predicts Prognosis and Immune Microenvironment for Non‐Small‐Cell Lung Cancer
Liu et al. A clinical nomogram based on absolute count of lymphocyte subsets for predicting overall survival in patients with non-small cell lung cancer
Zhao et al. Immune-related adverse events as independent prognostic factors for camrelizumab in patients with esophageal squamous cell carcinoma: a retrospective cohort study
Cao et al. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer
Qi et al. Development of a clinical prediction model for intra-abdominal infection in severe acute pancreatitis using logistic regression and nomogram
EP4158655B1 (de) Verfahren zur bestimmung des sterblichkeitsrisikos eines krebspatienten, verfahren zur beurteilung einer antikrebstherapie, verfahren zur auswahl von krebspatienten zur behandlung
HK40055890B (en) Cancer prognosis
HK40055890A (en) Cancer prognosis
Wang et al. Autophagy gene panel-based prognostic model in myelodysplastic syndrome
Nagai et al. Comparison of the Immune Checkpoint Inhibitor‐Free Survival Between Patients Who Completed and Those Who Discontinued ICI for Non‐Small Cell Lung Cancer
Zheng et al. A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer
Zhou et al. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of metastatic cancer patients to immune checkpoint inhibitors
Hernández-Yagüe et al. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment
McDonald et al. Change in overall survival associated with Karnofsky Performance Status over time
Thao The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of Ontario, Canada
Yuan Using Electronic Medical Records to Study Lung Cancer Prognosis
Jin et al. Dynamic variation and prognostic value of weight loss during radiotherapy in nasopharyngeal carcinoma: A large-scale cohort study

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20250217

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020054954

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20250723

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602020054954

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G01N0033574000

Ipc: G01N0033575000

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251124

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1816915

Country of ref document: AT

Kind code of ref document: T

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251023

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20251023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20260121

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20260121

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20260121

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020054954

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: L10

Free format text: ST27 STATUS EVENT CODE: U-0-0-L10-L00 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250723

26N No opposition filed

Effective date: 20260424